Adult RSV Hospitalizations: New Study Findings
- Respiratory syncytial virus (RSV) is a significant, yet often underestimated, public health concern for adults.
- The Centers for Disease Control and Prevention (CDC) estimates that RSV leads to 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among older adults.
- Researchers analyzed hospital statistics and insurance claims data from 1992 to 2021, focusing on respiratory and cardiorespiratory hospitalizations across three age groups: 18-59, 60-70, and 75 and older.
Uncover the latest findings: A groundbreaking global study reveals a definitive link between respiratory syncytial virus (RSV) activity and increased adult hospitalizations. Especially concerning for those 75 and older, this research underscores RSV’s significant impact on public health. Learn how this study, analyzing data from 15 countries, including the U.S., is reshaping our understanding of RSV’s burden. News Directory 3 brings you the critical insights, from varied hospitalization rates across age groups and nations. This information equips healthcare providers and pharmacists to better address this critical respiratory illness. Discover what’s next in the fight against RSV.
Global Study Highlights RSV’s Impact on Adult Hospitalizations
Respiratory syncytial virus (RSV) is a significant, yet often underestimated, public health concern for adults. Underdiagnosis, stemming from nonspecific symptoms and testing limitations, contributes to this issue. A recent study published in The Lancet introduces a new method for estimating RSV-related hospitalizations in adults, using clinical data from 15 countries.
The Centers for Disease Control and Prevention (CDC) estimates that RSV leads to 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among older adults. While RSV typically presents as mild, cold-like symptoms, it can be particularly dangerous for older adults, those with chronic conditions, and individuals in nursing homes. Severe symptoms include fever, wheezing, and breathing difficulties.
Researchers analyzed hospital statistics and insurance claims data from 1992 to 2021, focusing on respiratory and cardiorespiratory hospitalizations across three age groups: 18-59, 60-70, and 75 and older. The study, conducted in 15 countries including the United States, canada, Mexico, Spain and Japan, also incorporated methods from the Global Burden of Disease (GBD) study.
The study used models to determine the relationship between RSV activity and hospitalizations between 2015 and 2019, accounting for factors like seasonality and influenza activity. They then calculated the population attributable fraction (PAF) to determine RSV-attributable hospitalizations.
The findings revealed a significant link between RSV activity and increased hospitalizations. Hospitalization rates varied across age groups and countries. adults aged 75 and older experienced the highest rates, with New Zealand reporting 1,100.8 cardiorespiratory hospitalizations per 100,000 people. Spain had the lowest rates among adults aged 18 to 59, at 5.0 hospitalizations per 100,000.
The study underscores the global burden of RSV infection and provides crucial data for pharmacists and health care providers in making informed decisions about interventions and vaccinations for at-risk adults. Understanding the role of RSV in adult hospitalizations is key to improving public health strategies.
What’s next
Future research will focus on refining the models used in this study and expanding surveillance efforts to better understand the long-term impact of RSV and inform targeted prevention strategies, including vaccine development and distribution.